Bli medlem
Bli medlem

Du är här

2015-03-27

Galapagos NV: Publication of Annual Report 2014 and invitation to the Annual Shareholders' Meeting to be held on 28 April 2015

Mechelen, Belgium; 27 March 2015 - Galapagos NV (Euronext: GLPG)
has the honor to invite the Shareholders, Warrant Holders, Directors and
Statutory Auditor of the Company to the Annual Shareholders' Meeting that
will be held on Tuesday 28 April 2015 at 2:00 p.m. (CET) at the registered
office of the Company.

In order to be admitted to the Shareholders' Meeting, the holders of
securities issued by the Company must comply with article 536 of the Belgian
Companies Code and article 29 of the articles of association of the Company,
and fulfill the formalities and make the notifications described in the
convening notice.

The Annual Report 2014, convening notice, and other relevant documents can be
found
athttp://www.glpg.com/index.php/companyoverview/shareholder-information/sh...

About Galapagos

Galapagos(Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology
company specialized in the discovery and development of small molecule
medicines with novel modes of action, with a pipeline comprising three Phase
2 programs, two Phase 1 trials, five pre-clinical studies, and 25 discovery
small-molecule and antibody programs in cystic fibrosis, inflammation, and
other indications. In the field of inflammation, AbbVie and Galapagos signed
a collaboration agreement for the development and commercialization
offilgotinib. Filgotinib is an orally-available, selective inhibitor of JAK1
for the treatment of rheumatoid arthritis and potentially other inflammatory
diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. GLPG1205,a first-in-class inhibitor of GPR84, is currently being
tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients.
GLPG1690, a first-in-class inhibitor of autotaxin, has shown favorable safety
in a Phase 1 trial and is expected to enter Phase 2 in idiopathic pulmonary
fibrosis. AbbVie and Galapagos also signed a collaboration agreement in
cystic fibrosis to develop and commercialize molecules that address mutations
in the CFTR gene. PotentiatorGLPG1837is currently in a Phase 1 trial, and
corrector GLPG2222 is at the pre-clinical candidate stage. The Galapagos
Group, including fee-for-service subsidiary Fidelta, has approximately 400
employees, operating from its Mechelen, Belgium headquarters and facilities
in The Netherlands, France, and Croatia. Further information at:www.glpg.com

CONTACT

Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications&IR
Tel: +31 6 2291 6240
ir@glpg.com

Galapagos forward-looking statements

This release may contain forward-looking statements, including, without
limitation, expectations regarding the commercial potential of our product
candidates generally, all of which involve certain risks and uncertainties.
These statements are often, but are not always, made through the use of words
or phrases such as "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," "continues," "we
believe," "we intend," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such
forward-looking statements. Among the factors that may result in differences
are the inherent uncertainties associated with competitive developments,
clinical trial and product development activities, regulatory approval
requirements and estimating the commercial potential of our product
candidates. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
regulation.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire

HUG#1906958

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.